Pulse Biosciences (NASDAQ: PLSE) net income
Pulse Biosciences reported a net loss of $72.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $53.6m. Earnings per share were −$1.08.
Pulse Biosciences's best year of the last 10 was fiscal 2016. It reported a loss in 10 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$72.8m | — | −20,794.6% | −$1.08 |
| 2024 | −$53.6m | — | — | −$0.92 |
| 2023 | −$42.2m | — | — | −$0.88 |
| 2022 | −$58.5m | — | −8,357.9% | −$1.72 |
| 2021 | −$63.7m | — | −4,489.4% | −$2.28 |
| 2020 | −$49.9m | — | — | −$2.14 |
| 2019 | −$47.0m | — | −4,778.3% | — |
| 2018 | −$37.5m | — | −8,418.2% | — |
| 2017 | −$25.6m | — | −10,351.0% | — |
| 2016 | −$9.5m | — | −13,997.1% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Pulse Biosciences net income compared with its sector
By net income for its latest fiscal year, Pulse Biosciences ranks 299th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Pulse Biosciences, −20,794.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 297th | Sonida Senior Living | −$70.8m | −18.6% |
| 298th | AdaptHealth | −$70.8m | −2.2% |
| 299th | Pulse Biosciences | −$72.8m | −20,794.6% |
| 300th | Beta Bionics | −$73.2m | −73.0% |
| 301st | Tectonic Therapeutic | −$74.2m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Pulse Biosciences
- How much did Pulse Biosciences earn in fiscal 2025?
- Pulse Biosciences reported a net loss of $72.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $53.6m.
- What are the earnings per share of Pulse Biosciences?
- They were −$1.08 in fiscal 2025, compared with −$0.92 in fiscal 2024.
- Where does Pulse Biosciences rank in its sector by net income?
- It ranks 299th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Pulse Biosciences come from?
- From the annual report (Form 10-K) that Pulse Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Pulse Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Pulse Biosciences: the Pulse Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.